Form 4: Cyclerion Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Andrew Gottesdiener, a Director of Cyclerion Therapeutics, Inc., received 48,445 shares of common stock on September 9, 2026.
Summary
- Grant/award: acquired 48,445 Stock Option (Right to Buy) on September 9, 2026; holds 48,445 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Andrew Gottesdiener — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-09 | Grant/award | Stock Option (Right to Buy) | 48,445 | — | — | 48,445 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-09 | Grant/award (48,445 shares) |
Keywords
insider transaction, Form 4, KRSA, Korsana Biosciences, Inc., neutral, Andrew Gottesdiener
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.